Board of Directors

Dr. Barbara Krebs-Pohl has served on the Board of Directors since January 2026. She is a seasoned biotech executive with more than 25 years of global experience across R&D, business development, licensing, alliance management, portfolio management and strategic transformation. Her career includes a distinguished 20-year tenure at MorphoSys AG, where she held roles including Chief Business Officer, Chief Integration Officer, and Senior Vice President of Global Business Development & Licensing and Alliance Management. She played a central role in multiple high-value transactions, strategic partnerships, and the company’s evolution leading up to its eventual acquisition by Novartis. She currently serves as independent director of CASI Pharmaceuticals (Nasdaq), Chair of the Board of OneChain Immunotherapeutics (Spain), Managing Director of the Foundation of Stem Cell Therapy and Regenerative Medicine and Managing Director of Viopas Venture Consulting (Germany). Her scientific background includes a PhD focused on antibody technologies, combined with extensive early-career work in immunology and discovery research.

Dr. John Beadle has served on the Board of Directors since January 2026. He is an experienced biotechnology entrepreneur, physician, and senior executive with more than 25 years of global leadership across immunotherapy development, gene therapy, and oncology. He was the founding CEO of PsiOxus Therapeutics, where he advanced multiple clinical programs, secured major strategic partnerships, raised substantial capital, and built an IPO-ready organization. He currently serves as Non-Executive Chair of Vitarka Therapeutics and Non-Executive Director of Pneumagen, CamGene Therapeutics and Icosphere Biosciences. Earlier in his career, he co-founded PowderMed and contributed to the first clinical efficacy signal for a nucleotide-based vaccine, later supporting the company’s sale to Pfizer. He also held senior roles in R&D, product development, and global medical operations at GSK, Pfizer, PowderJect Pharmaceuticals, and Glaxo Wellcome.

Susanne Stuffers has served on the Board of Directors since April 2025. She holds an M.D. degree from the Erasmus University Rotterdam, Netherlands, and a Ph.D. degree in cancer biomedicine from the Norwegian Radiumhospital. She has broad experience in healthcare and life sciences, covering the sector from several angles. She was a management consultant in health care (public and private) and life sciences at EY, served in medical and commercial roles in the pharmaceutical industry (Novartis), and has clinical practice as a resident in oncology. She worked with Arctic Securities as an equity analyst covering the healthcare sector, before joining forces with T.D. Veen to co-found and lead P53 Invest. She has supported life science companies in different phases of development. She also served as member of the Board of Directors of Nykode from February 2019 until May 2021. 

Christian Åbyholm has served on the Board of Directors since January 2020. He is a partner at Andenæsgruppen, a shareholder of Nykode. His prior professional experience and past roles include M&A, business development and equity research with Norsk Hydro, Aker RGI, Morgan Stanley and Merrill Lynch. Christian is a CFA Charter holder, has an MBA from IMD, and holds a business degree (siviløkonom) from the Norwegian School of Economics and Business Administration. In addition, he completed the first two years of law school at the University of Oslo.

Trygve Lauvdal, Ph.D. has served on the Board of Directors since April 2025. He also served as an observer to the Board from December 2021, prior to which he served as a Board Member from April 2020. He is an Investment Director with RASMUSSENGRUPPEN AS, a shareholder of the Nykode. Prior to joining RASMUSSENGRUPPEN AS, he worked as an equity analyst with DNB Markets and as product manager with ABB. He has held several board positions with Norwegian companies. Trygve holds a Ph.D. in Engineering Cybernetics from the Norwegian University of Science and Technology (NTNU).